Antunes Marina Venzon, Raymundo Suziane, Wagner Sandrine Comparsi, Mattevi Vanessa Suñé, Vieira Natalia, Leite Renata, Reginato Fabiola, Capra Marcelo Zanella, Fogliatto Laura, Linden Rafael
Instituto de Ciências da Saúde, Universidade Feevale, Novo Hamburgo, RS, Brazil.
Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre-RS, Brazil.
Bioanalysis. 2015;7(16):2105-17. doi: 10.4155/bio.15.101.
Imatinib (IM) is widely used in treatment of chronic myeloid leukemia with target trough plasma concentrations above 1000 ng ml(-1). DBS can increase access to IM therapeutic drug monitoring.
IM was measured in the range 50-4000 ng ml(-1) by UHPLC-MS/MS using one 6 mm DBS in a fully validated method. IM was stable at DBS maintained at 40°C for 36 days. Plasma and DBS concentrations were highly correlated (r > 0.96). The use of a IM concentration target of 765 ng ml(-1) in DBS identified 93% of patients with plasma concentration below 1000 ng ml(-1).
IM can be measured in DBS using UHPLC-MS/MS with results comparable to those obtained in blood plasma.
伊马替尼（IM）广泛用于治疗慢性髓性白血病，目标谷血浆浓度高于1000 ng/ml。干血斑可增加伊马替尼治疗药物监测的可及性。
采用经全面验证的方法，使用一块6 mm干血斑通过超高效液相色谱-串联质谱法在50 - 4000 ng/ml范围内测定伊马替尼。伊马替尼在40°C保存36天的干血斑中保持稳定。血浆和干血斑浓度高度相关（r > 0.96）。使用干血斑中伊马替尼浓度目标值765 ng/ml可识别出93%血浆浓度低于1000 ng/ml的患者。
可使用超高效液相色谱-串联质谱法在干血斑中测定伊马替尼，结果与血浆中获得的结果相当。
